

Companion Diagnostics:

From Early Drug Discovery to Clinical Applications

Oxford Belfry, Oxford, 1st May 2012



SAGENTIA

www.elrig.org

Somalogic





Welcome Words

Welcome to everyone and thank you for coming to ELRIG's first meeting of 2012. This meeting focuses on the emerging area of Companion Diagnostics, here at the impressive and world famous setting of The Belfry, at Oxford.

We are delighted to present an enticing programme of top quality speakers from academia and industry who will be covering some world class research in what promises to be an entertaining and informative program of lectures and discussions. The scientific program will also be complemented by a poster session and a vendor exhibition, giving attendees the opportunity to review the latest developments in both reagents and instrumentation in this important and growing field.

As you may know, ELRIG is a not-for-profit organisation whose aim is to support the development of our industry by organising free-to-attend scientific conferences, as well as offering training awards and bursaries and I would urge all of you to join ELRIG's community to either help or benefit from what we do. In order to do this, ELRIG run trade exhibitions in parallel to the scientific conferences and I would urge all of the delegates to visit our vendors here today because without them this Companion Diagnostics and our other conferences, would not be possible.

Also, as a not-for-profit organisation, ELRIG is dependent on a number of volunteers to aid in the organisation of our events and I would like to offer them and the Scientific Committee, ably led by Neil Campbell, a very special thank you for bringing us today's program.

We also thank the ELRIG staff: Jackie Howard and Dermot Boylan for their efforts in ensuring that the conference actually happens and is a typical ELRIG success.

We hope you enjoy your time with us today and will continue to support ELRIG in our Future Events.

Terry Wood

Chairman

Future Meetings 2013

19th March 2013

Research & Innovation 1 Day – 3 Track meeting

Telford International Centre

June 2013

Pharma Meeting

3rd and 4th September 2013

Drug Discovery: 2013

Manchester Central

For more information please contact:

Jackie Howard at jackie.howard@elrig.org or Dermot Boylan at dermot.boylan@elrig.org

Exhibitors

Sagentia	SAGENTIA
SomaLogic*	Somalogic
Dynex Technologies	DYNEX
Qiagen	QIAGEN
Bioscale	BIOSCALE
Liconic Instruments	LICONIC INSTRUMENTS
Roche Applied Science	Roche

SAGENTIA

Sagentia is a global innovation, technology and product development providing outsourced R&D consultancy to the medical, industrial and consumer sectors. Working with medical clients ranging from early stage start-ups through to world-leading healthcare companies, we have a proven track record in the design and development of laboratory instrumentation and handheld devices.

Entering the new era of personalised medicine, we are now seeing increased activity around companion diagnostics. Depending on what you are testing for, you need to understand the context and scenarios of use for your companion diagnostic. What sensitivity & specificity are required from the test? What detection technologies are relevant? What levels of test throughput will the platform see? These are all questions that a companion diagnostic development programme will need to consider. Sagentia has developed platforms for all categories of diagnostics including home-use disposables, handheld analysers, Near-Patient & Point-of-Care (PoC), through to large high throughput benchtop instruments in central laboratories. All these projects utilise our expertise in high volume consumable development, microfluidics, optics, usability and assay integration.

Previous projects include systems focused on clinical chemistry, haemostasis, immunoassays and molecular diagnostics. More recently, we have worked on systems concerned with genomics and proteomics, key enabling technologies for personalised medicine and the devices that enable it.

www.sagentia.com

Somalogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado, USA. The company's mission is to use its breakthrough proteomic technology to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and accurate diagnostic information to physicians and their patients.

SomaLogic's proprietary SOMAscan™ multiplex proteomic technology platform can accurately detect and measure thousands of proteins over a large range of concentrations in small sample volumes. We are delighted to launch our UK SomaSciences division (which provides access to SOMAscan) at ELRIG and encourage participants to talk to us about how we can help unlock their protein biomarker needs.

www.somalogic.com







Speaker **Programme**

Oxford Belfry, Oxford 1st May 2012

8.30 – 9.15	Registration	
9.15 - 9.20 9.20 - 9.25	Opening Remarks Welcome	Neil Campbell, Conference Director from ELRIG
9.25 – 9.30	Introductions	Session Chairs – Helen Ambrose, AstraZeneca & Sean Tyacke, Roche
9.30 – 10.15	Michael Berndt, Dublin City Uni	"Integrating platform technologies into point-of-care diagnostics"
10.15 – 10.45	Austin Tanney, Almac Group	"Development & Commercialisation of Companion Diagnostics from Biomarkers"
10.45 – 11.15	COFFEE/EXHIBITION	
11.15 – 11.45	Hayley Whitaker, Cancer UK	"A robust pipeline from bench to bedside in academic research"
11.45 – 12.15	James Sherwood, AstraZeneca	"Challenges and Opportunities in Developing Companion Diagnostics"
12.15 – 12.45	Snapshots	BioScale, Sagentia, Somalogic
12.45 – 2.15	LUNCH/EXHIBITION	Poster Viewing
2.15 – 2.45	Lisa Thompson, The Royal Marsden Hospital NHS Foundation Trust	"Molecular Diagnostics in Cancer Care – challenges for implementation"
2.45 – 3.15	Peter Hamilton, Queens, Belfast	"Digital Pathology & Tissue Imaging for Biomarker Validation and Companion Diagnostics"
3.15 – 3.45	COFFEE/EXHIBITION	
3.45 – 4.15	Steve Williams, Somalogic	"Unlocking protein biomarker discovery for diagnostics and therapeutics; Rapid translation to diagnostic products"
4.15 – 4.45	Paul Wilkins, Sagentia	"Keeping your options open – balancing "time to market" and "platform flexibility" in your diagnostic development cycle"
4.45 – 5.00	CLOSE/PRIZE DRAW	





ELRIG 2012 Meetings



26th June 2012 NGS – Technologies & Future Applications

Hinxton Hall, Cambridge



Hinxton Hall, Cambridge



Manchester Central

1: Assay Development & Screening

2: Fragment Discovery for Enzyme & Membrane Targets

3: Primary Cells & Stem Cells in Discovery

4: The Ubiquitin Cascade Biology & Drug Discovery

5. Advances in Liquid Handling & Detection Technologies

6. Compound Collection Management & Enhancement

7. Epigenetic Drug Discovery

8. Biophysics & Label Free Detection Technologies

Daily Lunchtime **Seminar:** Informatics – Making Knowledge from Lab Data



Manchester Central



AZ, Alderley Park

10th and 11th October 2012 Pharmaceutical Flow Cytometry & Imaging

AstraZeneca R&D, Alderley Park





Jackie Howard Email: events@elrig.org Tel: 0845 017 0517



Founding **Sponsors**



















